THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Drug firms' funding of advocates often escapes government scrutiny

Many patient groups depend on it, raising tricky ethical questions

By Diedtra Henderson
Globe Staff / March 18, 2007

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

WASHINGTON -- Elzora K. Brown could stand before a microphone and calmly describe the swath of devastation that cancer has cut through five generations of her family. Her great-grandmother, grandmother, mother, three sisters, and three nieces had breast cancer . And, at age 31 , Brown was diagnosed with the same kind of cancer. (Full article: 1772 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass